Search research articles
Contact Us
Filters
Showing results (41-50 of 82) with videos related to
Page
of 9
Sort By:
Cancer Chemotherapy and Pharmacology
|
May 14, 2015
Phase II trial of everolimus in patients with refractory metastatic adenocarcinoma of the esophagus, gastroesophageal junction and stomach: possible role for predictive biomarkers
Zev A Wainberg, Heloisa P Soares, Ravi Patel, et al.
Journal of Geriatric Oncology
|
July 9, 2014
Physical function and quality of life in frail and/or elderly patients with metastatic colorectal cancer treated with capecitabine and bevacizumab: an exploratory analysis
Peter Ward, J Randolph Hecht, He-Jing Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 23, 2025
Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas
Jason J Luke, Randy F Sweis, J Randolph Hecht, et al.
Journal of the National Cancer Institute
|
March 20, 2020
Threshold Change in CEA as a Predictor of Non-Progression to First-Line Systemic Therapy in Metastatic Colorectal Cancer Patients With Elevated CEA
Pat Gulhati, Jun Yin, Levi Pederson, et al.
Journal of Geriatric Oncology
|
January 30, 2014
A phase II trial of frontline capecitabine and bevacizumab in poor performance status and/or elderly patients with metastatic colorectal cancer
Arash Naeim, Peter R Ward, Hei-Jing Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 6, 2011
Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma
Eric Van Cutsem, Emilio Bajetta, Juan Valle, et al.
Nature
|
June 23, 2012
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Luis A Diaz, Richard T Williams, Jian Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 19, 2021
A Randomized Phase II Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab in Patients with Advanced Gastrointestinal Stromal Tumors
Arun S Singh, J Randolph Hecht, Lee Rosen, et al.
Targeted Oncology
|
March 27, 2025
A Phase 1b/2 Study of the Anti-CD47 Antibody Magrolimab with Cetuximab in Patients with Colorectal Cancer and Other Solid Tumors
Cathy Eng, Nehal J Lakhani, Philip A Philip, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 6, 2011
Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma
J Randolph Hecht, Tanja Trarbach, John D Hainsworth, et al.
Page
of 9
Search research articles
Search
Showing results (41-50 of 82) with videos related to
Sort By:
Page
of 9
Cancer Chemotherapy and Pharmacology
|
May 14, 2015
Phase II trial of everolimus in patients with refractory metastatic adenocarcinoma of the esophagus, gastroesophageal junction and stomach: possible role for predictive biomarkers
Zev A Wainberg, Heloisa P Soares, Ravi Patel, et al.
Journal of Geriatric Oncology
|
July 9, 2014
Physical function and quality of life in frail and/or elderly patients with metastatic colorectal cancer treated with capecitabine and bevacizumab: an exploratory analysis
Peter Ward, J Randolph Hecht, He-Jing Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 23, 2025
Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas
Jason J Luke, Randy F Sweis, J Randolph Hecht, et al.
Journal of the National Cancer Institute
|
March 20, 2020
Threshold Change in CEA as a Predictor of Non-Progression to First-Line Systemic Therapy in Metastatic Colorectal Cancer Patients With Elevated CEA
Pat Gulhati, Jun Yin, Levi Pederson, et al.
Journal of Geriatric Oncology
|
January 30, 2014
A phase II trial of frontline capecitabine and bevacizumab in poor performance status and/or elderly patients with metastatic colorectal cancer
Arash Naeim, Peter R Ward, Hei-Jing Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 6, 2011
Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma
Eric Van Cutsem, Emilio Bajetta, Juan Valle, et al.
Nature
|
June 23, 2012
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Luis A Diaz, Richard T Williams, Jian Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 19, 2021
A Randomized Phase II Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab in Patients with Advanced Gastrointestinal Stromal Tumors
Arun S Singh, J Randolph Hecht, Lee Rosen, et al.
Targeted Oncology
|
March 27, 2025
A Phase 1b/2 Study of the Anti-CD47 Antibody Magrolimab with Cetuximab in Patients with Colorectal Cancer and Other Solid Tumors
Cathy Eng, Nehal J Lakhani, Philip A Philip, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 6, 2011
Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma
J Randolph Hecht, Tanja Trarbach, John D Hainsworth, et al.
Page
of 9